BridgeBio: FDA accepts infigratinib NDA for achondroplasia, grants priority review

BridgeBio won FDA Priority Review for its NDA of oral infigratinib to treat children with achondroplasia. PDUFA target action date set for Feb. 4, 2027. Approval would make infigratinib the first FDA-cleared oral therapy for achondroplasia.